Tabelecleucel - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Drug Profile

Tabelecleucel - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center

Alternative Names: ATA-129; EBV targeted T-cell therapy - Atara/MSKCC; EBV-CTL - Atara/MSKCC; EBV-specific T-cells - Atara/MSKCC; Epstein-Barr virus specific cytotoxic T-lymphocytes - Atara/MSKCC; Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics/Memorial Sloan-Kettering Cancer Center; Epstein-Barrr-virus-specific-cytotoxic-T-lymphocytes-Atara/MSKCC; Tab-cel™

Latest Information Update: 06 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA)
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphoproliferative disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase III Lymphoproliferative disorders

Most Recent Events

  • 01 Aug 2018 The US FDA accepts IND for a phase I/II trial for Nasopharyngeal carcinoma (Combination therapy) in USA
  • 15 Jun 2018 Updated safety and efficacy data from phase II trials in Lymphoproliferative disorders presented at the 23rd Congress of European Haematology Association (EHA-2018)
  • 14 Jun 2018 Long term safety and efficacy data from phase II trials in Lymphoproliferative disorders were presented at the 23rd Congress of the European Haematology Association (EHA-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top